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Cerebral Folate Deficiency Syndrome
to the editor: Ramaekers et al. (May 12 issue)1
report 28 patients with the cerebral folate defi-
ciency syndrome characterized by decreased lev-
els of 5-methyltetrahydrofolate (5MTHF) in the
cerebrospinal fluid caused by autoantibodies’ block-
ing of folate transport into the brain. The patients
benefited from folinic acid supplementation.
The clinical features of this syndrome fit with
other neurodegenerative disorders. According to
previous papers by the authors, the latter disorders
can be associated with cerebral folate deficiency as
a secondary phenomenon.2-4 Patients with second-
ary cerebral folate deficiency (e.g., the Rett syn-
drome) potentially benefit from folinic acid sup-
plementation.2-4 The authors do not report the
presence or absence of folate-receptor autoantibod-
ies in secondary cerebral folate deficiency. Before
claiming that the cerebral folate deficiency syn-
drome is a separate entity, the investigators should
demonstrate that it is a unique, autoantibody-medi-
ated disease, different from secondary cerebral
folate deficiency.
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the authors reply: Within the group of neuro-
psychiatric conditions associated with cerebral
folate deficiency, infantile-onset cerebral folate de-
ficiency syndrome can be delineated as a separate
and recognizable clinical entity, which can begin
manifesting itself at the age of four months, when
the only identifiable abnormality is a low level of
5MTHF in the cerebrospinal fluid.1,2 This means
that other conditions that involve secondary cere-
bral folate deficiency must be excluded before a
firm diagnosis of infantile cerebral folate defi-
ciency syndrome is established.2
The identification of blocking folate-receptor
autoantibodies in the serum of most patients with
infantile-onset cerebral folate deficiency syndrome
merely reflects a specific autoimmune mechanism
that explains the blocked folate transfer to the brain.
Among the few patients without these folate-recep-
tor autoantibodies, alternative causes may be re-
sponsible for the low levels of 5MTHF in cerebro-
spinal fluid.
Since blocking folate-receptor autoantibodies
impair folate transport across the placenta and
blood–cerebrospinal fluid barriers,3 we cannot ex-
clude the possibility that they also play a role in
the pathogenesis of secondary cerebral folate de-
ficiency.4,5
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Response of a Nonmalignant Pleural Effusion to Bevacizumab
to the editor: The potential role of vascular en-
dothelial growth factor in malignant as well as non-
malignant pleural effusion1,2 prompted us to use
bevacizumab, a monoclonal antibody against vas-
cular endothelial growth factor, in a 68-year-old
man with primary cardiac amyloidosis who had se-
vere dyspnea and underwent repeated thoracenteses
for pleural effusions. Cytologic assessments of the
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